| Assessment Status | Rapid Review Complete |
| HTA ID | 26039 |
| Drug | Pegcetacoplan |
| Brand | Aspaveli® |
| Indication | Pegcetacoplan (Aspaveli®) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (ICMPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated. |
| Assessment Process | |
| Rapid review commissioned | 06/08/2026 |
| Rapid review completed | 03/09/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pegcetacoplan for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here